Coumarins and survival in incident dialysis patients

Nephrology Dialysis Transplantation

Volumn 27, Issue 1, 2012, Pages 332-337

  Knoll, Florian ^a   Sturm, Gisela ^b   Lamina, Claudia ^b   Zitt, Emanuel ^a,c   Lins, Friederike ^c   Freistätter, Otto ^c   Kronenberg, Florian ^b   Lhotta, Karl ^a,c   Neyer, Ulrich ^a,c  

^a Academic Teaching Hospital Feldkirch   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Landeskrankenhaus Feldkirch   (Austria)

Author keywords

atrial fibrillation; coumarins; end stage renal disease; oral anticoagulation; survival

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; COUMARIN DERIVATIVE; HEMOGLOBIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG MONITORING; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SINUS RHYTHM; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; AUSTRIA; COUMARINS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; STROKE; SURVIVAL RATE;

EID: 84856661011     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr341     Document Type: Article

References (34)

1. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952 (Pubitemid 28446646)
2. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867 (Pubitemid 351650486)
4. Genovesi S, Pogliani D, Faini A et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005; 46: 897-902 (Pubitemid 41505464)
5. Chan KE, Lazarus JM, Thadhani R et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20: 2223-2233
6. Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol 2008; 3: 1504-1510
7. Sanchez-Perales C, Vazquez E, Garcia-Cortes MJ et al. Ischaemic stroke in incident dialysis patients. Nephrol Dial Transplant 2010; 25: 3343-3348
8. Seliger SL, Gillen DL, Longstreth WT Jr et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64: 603-609 (Pubitemid 36871932)
9. Abbott KC, Trespalacios FC, Taylor AJ et al. Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospital-ization and mortality. BMC Nephrol 2003; 4: 1
10. Sturm G, Lamina C, Zitt E et al. Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients. Nephrol Dial Transplant 2010; 25: 2715-2722
11. Schwaiger JP, Lamina C, Neyer U et al. Carotid plaques and their predictive value for cardiovascular disease and all-cause mortality in hemodialysis patients considering renal transplantation: a decade follow-up. Am J Kidney Dis 2006; 47: 888-897
12. Schwaiger JP, Neyer U, Sprenger-Mahr H et al. A simple score predicts future cardiovascular events in an inception cohort of dialysis patients. Kidney Int 2006; 70: 543-548 (Pubitemid 44141581)
13. US Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005
14. Vazquez E, Sanchez-Perales C, Garcia-Garcia F et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009; 76: 324-330
15. Wizemann V, Tong L, Satayathum S et al. Atrial fibrillation in he-modialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int; 2010; 77: 1098-1106
16. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375 (Pubitemid 32424106)
17. Langenberg M, Hellemons BS, van Ree JW et al. Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ 1996; 313: 1534 (Pubitemid 27016893)
18. Wiesholzer M, Harm F, Tomasec G et al. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 2001; 21: 35-39 (Pubitemid 32238611)
19. Genovesi S, Vincenti A, Rossi E et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008; 51: 255-262
20. Chan KE, Lazarus JM, Thadhani R et al. Anticoagulant and antipla-telet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20: 872-881
21. Cranenburg EC, Vermeer C, Koos R et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res 2008; 45: 427-436
22. Krueger T, Westenfeld R, Ketteler M et al. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Kidney Int 2009; 76: 18-22
23. Rennenberg RJ, van Varik BJ, Schurgers LJ et al. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010; 115: 5121-5123
24. Koos R, Krueger T, Westenfeld R et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 2009; 101: 706-713
25. Saran R, Dykstra DM, Wolfe RA et al. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2002; 40: 1255-1263 (Pubitemid 35403138)
26. Crowther MA, Clase CM, Margetts PJ et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002; 13: 2331-2337 (Pubitemid 34925243)
27. Tschugguel W, Blaicher A, Kramer L et al. Platelet disorders in uraemia before and after haemodialysis under the influence of low dose aspirin. Thromb Res 1995; 80: 225-233
28. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902 (Pubitemid 24179151)
29. Baker WL, Cios DA, Sander SD et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15: 244-252
30. van Walraven C, Jennings A, Oake N et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155-1166
31. Sood MM, Rigatto C, Bueti J et al. Thrice weekly warfarin administration in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 3162-3167
32. Holden RM, Harman GJ, Wang M et al. Major bleeding in hemodial-ysis patients. Clin J Am Soc Nephrol 2008; 3: 105-110
33. Biggers JA, Remmers AR Jr, Glassford DM et al. The risk of anti-coagulation in hemodialysis patients. Nephron 1977; 18: 109-113
34. Vazquez E, Sanchez-Perales C, Borrego F et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000; 140: 886-890